Quarterly report pursuant to Section 13 or 15(d)

Condensed Consolidated Financial Statements Detail

v3.5.0.2
Condensed Consolidated Financial Statements Detail
6 Months Ended
Jun. 30, 2016
Condensed Consolidated Financial Statements Detail [Abstract]  
Condensed Consolidated Financial Statements Detail

3. Condensed Consolidated Financial Statements Detail

Cash and Cash Equivalents

As of June 30, 2016, cash and cash equivalents consisted of demand deposits of $5.8 million and money market funds of $28.1 million with maturities of less than 90 days at the date of purchase. As of December 31, 2015, cash and cash equivalents consisted of demand deposits of $23.2 million and money market funds of $42.6 million with maturities of less than 90 days at the date of purchase.

Marketable Securities

At June 30, 2016 and December 31, 2015, marketable securities consisted of an investment in the common stock of a public entity of $0.4 million and $0.5 million, respectively. The Company had an unrealized loss of $0.1 million associated with its marketable securities as of June 30, 2016. At each reporting date, the Company performs an evaluation of its equity securities to determine if unrealized losses are other-than-temporary. In performing this assessment, the Company determines whether it expects the security to recover in the near term and considers its ability and intent to hold the security until anticipated recovery. This determination considers the duration and severity of the impairment and the financial condition of the investment as well as the Company’s ability to hold the investment until a recovery of fair value. As of June 30, 2016, the Company determined that the unrealized loss for its marketable securities is not an other-than-temporary impairment.

Accrued and Other Liabilities  

Accrued and other liabilities consisted of the following (in thousands):

 

 

 

June 30,

 

 

December 31,

 

 

 

2016

 

 

2015

 

Accrued payroll and other benefits

 

$

1,627

 

 

$

2,156

 

Accrued clinical trial costs

 

 

1,451

 

 

 

406

 

Accrued incentive compensation

 

 

915

 

 

 

2,609

 

Deferred rent

 

 

757

 

 

 

608

 

Accrued legal and accounting fees

 

 

299

 

 

 

517

 

Other

 

 

688

 

 

 

729

 

Total

 

$

5,737

 

 

$

7,025

 

 

Net Loss Per Share of Common Stock

Potentially dilutive securities are excluded from the calculation of diluted net loss per share of common stock if their inclusion is anti-dilutive.

The following table shows the weighted-average outstanding securities considered anti-dilutive and therefore excluded from the computation of diluted net loss per share of common stock (in thousands):

 

 

 

Three  Months Ended June 30,

 

 

Six Months Ended June 30,

 

 

 

2016

 

 

2015

 

 

2016

 

 

2015

 

Common stock options and RSUs

 

 

9,345

 

 

 

8,362

 

 

 

9,476

 

 

 

7,850

 

Warrants for common stock

 

 

18,331

 

 

 

19,087

 

 

 

18,280

 

 

 

19,087

 

Total

 

 

27,676

 

 

 

27,449

 

 

 

27,756

 

 

 

26,937